S5E04: Engineering Therapeutic Antibodies

Small molecules, antibodies, gene therapies – there are so many types of medicines scientists can consider when developing a new treatment for a disease. In this episode, Karin Briner, Senior Vice President and Head of Drug Discovery, joins co-host Maria Wilson to break down different therapeutic modalities, or types of treatments. Together, they cover a wide range of modalities in our drug development toolbox – including RNA-based therapies, large molecules, cell therapies, and newer small molecule approaches like protein degraders – highlighting the challenges and opportunities presented by each while also providing a look ahead to innovations that could lead to more effective treatments for a range of diseases. Read the full text transcript at www.gene.com/stories/a-deep-dive-into-drug-modalities

Did you know that scientists can grow three-dimensional, miniature versions of human organs in a dish? These tiny in vitro models, known as organoids, are helping scientists to better understand human disease and to test new treatments. In this episode, co-host Danielle Mandikian sits down with Kim Homan, Senior Director and Distinguished Scientist, Complex in vitro Systems Lab, to discuss the fascinating world of organoids and organ-on-chip technologies. They delve into how these systems are transforming drug development, where AI and ML come into play, and how organoid models could lead to more accurate predictions, better clinical studies, and improved patient outcomes. Read the full text transcript at www.gene.com/stories/organoids-from-dish-to-discovery

To defeat cancer, we need to understand it better. How does it grow? How do we detect it early? And most importantly, how do we treat it? In this episode, co-host Maria Wilson chats with oncology expert Louis Vermeulen, VP and Senior Fellow, Discovery Oncology, about what’s new and exciting in cancer research. Together, they explore the importance of early detection, explain concepts like the tumor microenvironment, discuss cancer treatment approaches, and dive into how tools like artificial intelligence are accelerating research in the oncology space. Read the full text transcript at www.gene.com/stories/cancer-conversations-early-detection-and-potent-solutions

What drives metabolic conditions like obesity? In this special episode, co-host and cardiovascular disease expert Maria Wilson, gRED Executive Director and Cardiovascular and Metabolism Research Head, takes the hot seat with fellow host Danielle Mandikian, gRED Senior Principal Scientist, to discuss the complex world of obesity. Tune in to hear about the biological and environmental factors contributing to this chronic disease, its profound effects on health, societal implications, as well as the latest and upcoming treatment approaches for obesity and related metabolic conditions. Read the full text transcript at www.gene.com/stories/the-streets-and-deets-of-obesity

Antibodies are proteins produced by our immune system that neutralize or help destroy abnormal cells and foreign agents, like bacteria and viruses. However, their utility extends beyond our bodies’ defense system. Antibodies can also be engineered in the lab to be used as therapies. Today, over 170 antibodies have been approved as medicines to treat a wide range of diseases including cancers, autoimmune diseases, infectious diseases and more. In this episode, co-host Maria Wilson chats with guests Yan Wu, VP and Senior Fellow, Antibody Engineering, and Paul Carter, Genentech Fellow, Antibody Engineering, to discuss all things antibodies! Learn about the history of therapeutic antibodies, how advances in antibody engineering are creating new classes of medicines, and the promising role of artificial intelligence in designing antibodies from scratch and optimizing their therapeutic activity. Read the full text transcript at www.gene.com/stories/engineering-therapeutic-antibodies

Many health conditions require medicines that can be delivered to specific parts of the body. For instance, someone with asthma requires medication that targets the lungs, while someone with a neurodegenerative disease needs therapeutics that can penetrate the blood-brain barrier. But how do scientists create medicines that not only reach their intended targets but also produce the desired pharmacological effect while minimizing side effects and ensuring convenience for the patient? In this episode, co-host Danielle Mandikian chats with Karthik Nagapudi, Executive Director of Pharmaceutics, to explore the pivotal role of drug delivery strategies, highlighting how incorporating drug delivery considerations from the initial stages of drug development is crucial for creating next-generation medications. Read the full text transcript at www.gene.com/stories/no-delivery-no-drug

Imagine the eyes as cameras, where the cornea acts as the lens and the retina as the film. As with a camera, if something goes wrong in the eye, it needs to be fixed to address the specific problem and restore function. While some visual impairments can be corrected with glasses or surgery, some conditions require medicines – like those that slow or stop blood vessel growth in the eye. In this episode, co-host Danielle Mandikian joins guests Chris Brittain, Vice President and Global Head of Ophthalmology Product Development, and Dolly Chang, Group Medical Director, gRED Early Clinical Development, to explore the evolution of eye treatments, advancements in current solutions for vision loss, and their insights into the future of treating ocular diseases. Read the full text transcript at www.gene.com/stories/seeing-clearly-the-past-present-and-future-of-eye-treatment

Computational approaches have revolutionized how we interpret data. With the advent of genomic sequencing, scientists can derive significant conclusions from sequence data. For example, through transcriptomics – the study of genes and their expression in different cells – researchers have made groundbreaking discoveries in fields like developmental and disease biology. More recently, computational approaches have expanded with the introduction of generative artificial intelligence (AI) and its ability to generate new insights from massive datasets, diverse in scope, which can be validated in the lab. In this episode, co-host Maria Wilson sits down with John Marioni, Senior Vice President and Head of Computational Sciences, to discuss how computational methods can complement other research techniques to expedite drug discovery, enhance clinical trials, and prevent biases, ensuring the development of medicines that can treat people of diverse backgrounds. Read the full text transcript at www.gene.com/stories/merging-minds-and-machines-the-future-of-drug-discovery

Join Danielle Mandikian and Maria Wilson as they kick off season five of Two Scientists Walk Into a Bar. Hear about their recent lab adventures and enjoy a sneak preview of exciting topics for our new season. From demystifying the impact of AI and machine learning in drug development to exploring diverse modalities for treating diseases, we've got an exciting lineup in store. Subscribe today so you don’t miss an episode! Read the full text transcript at: www.gene.com/stories/season-five-teaser

When we consider how a vaccine works, we typically think about vaccines that prevent infectious disease like flu or measles. But another type, known as therapeutic vaccines, may be able to treat diseases even after they’ve taken hold in the body – including cancer and viral infections. Similar to preventative vaccines, these therapeutic cancer vaccines work by promoting an immune response. Cancer vaccines are an emerging approach that have the potential to train the immune system to better seek out and destroy cancer cells. Co-host Danielle Mandikian sits down with Lélia Delamarre, Director and Distinguished Scientist, Cancer Immunology, and Ina Rhee, Executive Group Medical Director, Oncology Early Clinical Development, to discuss the fascinating science behind cancer vaccines as well as current challenges and opportunities. Read the full text transcript at https://www.gene.com/stories/learning-from-vaccines-training-our-immune-system-to-fight-cancer